The Sirtuin family: therapeutic targets to treat diseases of aging

被引：237

作者：

Milne, Jill C. ^{[1
]}

Denu, John M. ^{[2
]}

机构：

[1] Sirtris Pharmaceut Inc, Cambridge, MA 02139 USA

[2] Univ Wisconsin, Sch Med, Madison, WI 53706 USA

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 2008年 / 12卷 / 01期

关键词：

D O I：

10.1016/j.cbpa.2008.01.019

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Sirtuins have emerged as therapeutic targets to treat age-related diseases. There are seven human Sirtuins (SIRT1-7) that display diversity in cellular localization and function. Growing evidence suggests that small-molecule activators of SIRT1 may counteract age-related afflictions such as type 2 diabetes. Alternatively, inhibitors of SIRT2 may be useful in the treatment of neurodegenerative diseases such as Parkinson's disease. Recent discoveries of small-molecule and protein modulators of Sirtuin deacetylation activity have provided enormous insight into the biological and molecular functions of Sirtuins and have validated their potential as therapeutics.

引用

页码：11 / 17

页数：7

共 52 条

[51] Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-κB in macrophages in vitro and in rat lungs in vivo:: implications for chronic inflammation and aging [J].